Kawasaki’s disease

1. High-Yield Summary

• Definition and Primary Target: Kawasaki disease (mucocutaneous lymph node syndrome) is an acute, self-limited, systemic vasculitis of small- to medium-sized muscular arteries with a predilection for the coronary arterial circulation. It represents the leading cause of acquired pediatric heart disease in developed nations, occurring primarily in infants and young children (80% to 85% aged under 5 years, with peak incidence between 18 and 24 months).
• The Orthopaedic Trap (Pediatric Septic Arthritis Mimic): Musculoskeletal manifestations occur in 15% to 30% of patients, frequently presenting during the acute febrile phase as an acute oligoarthritis or monoarthritis of large weight-bearing joints (knees, hips, ankles) accompanied by severe refusal to bear weight. This presentation frequently fulfills Kocher criteria for septic arthritis, prompting unwarranted emergent surgical arthrotomies and joint debridements before the underlying vasculitis is identified.
• Coronary Artery Aneurysm Risk: Without timely medical therapy, 20% to 25% of affected children develop coronary artery aneurysms (CAA), predisposing to acute myocardial infarction, ischemic heart disease, and sudden cardiac death. Early administration of high-dose intravenous immunoglobulin (IVIG) combined with aspirin within the first 10 days of fever onset suppresses coronary vasculitis and reduces the aneurysm rate to less than 3% to 5%.
• Diagnostic Benchmarks: The diagnosis is clinical, established by persistent unexplained fever lasting 5 days or longer alongside at least 4 of 5 classic clinical criteria: (1) bilateral non-exudative bulbar conjunctival injection with perilimbal sparing; (2) oropharyngeal mucosal changes (strawberry tongue, erythematous cracked lips); (3) polymorphous, non-vesicular exanthem; (4) peripheral extremity changes (acute erythema and non-pitting induration of hands and feet, followed by convalescent periungual desquamation); and (5) unilateral non-suppurative cervical lymphadenopathy (at least 1.5 cm diameter). Incomplete (atypical) presentations are common in infants under 6 months, who carry the highest risk of giant aneurysms.
• Definitive Management Pathway: Immediate first-line therapy consists of a single high-dose IVIG infusion (2 g/kg over 10 to 12 hours) co-administered with aspirin (anti-inflammatory dosing 30 to 50 mg/kg/day or 80 to 100 mg/kg/day in the acute phase, transitioning to antiplatelet dosing 3 to 5 mg/kg/day once afebrile for 48 to 72 hours). High-risk patients identified via risk scoring models (such as the Kobayashi score) benefit from primary adjunctive systemic corticosteroids. Synovial inflammation resolves completely with medical therapy, requiring no surgical joint drainage.

2. Anatomy

A comprehensive clinical and orthopaedic understanding of Kawasaki disease requires an analysis of medium-vessel arterial architecture, the microanatomy of synovial joints, cervical lymphatic anatomy, and peripheral digital microvascular beds.

Coronary Arterial Microarchitecture and Aneurysm Topography

Kawasaki disease exhibits a specific predilection for medium-sized muscular arteries, with the coronary arterial circulation representing the primary site of catastrophic tissue damage. The arterial wall possesses three distinct structural tunics:

• Tunica Intima: Composed of a continuous luminal monolayer of non-thrombogenic endothelial cells resting upon a delicate subendothelial connective tissue layer, bounded externally by the internal elastic lamina. In Kawasaki disease, rapid endothelial activation and disruption of this lamina compromise luminal barrier integrity.
• Tunica Media: Composed of multiple concentric layers of circumferentially arranged vascular smooth muscle cells (VSMC) embedded within an extracellular matrix of elastin, type III collagen, and proteoglycans, bounded externally by the external elastic lamina. Destruction of this muscular-elastic skeleton under intense enzymatic breakdown is the biomechanical trigger for aneurysm formation.
• Tunica Adventitia: A robust outer fibrous sheath composed of longitudinally oriented collagen bundles, fibroblasts, and the microvascular vasa vasorum that supply the outer media. Transmural inflammatory cell infiltration tracks inward through these adventitial vessels.

Coronary aneurysms demonstrate distinct anatomical localization patterns:

• Proximal Left Anterior Descending (LAD) Artery: The most common site of dilation and aneurysm formation, located immediately distal to the bifurcation of the left main coronary artery (LMCA).
• Proximal Right Coronary Artery (RCA): The second most common site, specifically involving the proximal horizontal and mid-vertical segments within the right atrioventricular groove.
• Left Main Coronary Artery (LMCA) and Left Circumflex (LCx) Artery: Moderately frequent sites of proximal dilation. Saccular aneurysms in the short LMCA trunk carry an exceptionally high risk of catastrophic myocardial infarction.
• Distal Coronary Branches and Systemic Muscular Arteries: Distal epicardial branches are rarely involved in isolation. Peripheral aneurysms may develop in systemic medium arteries, including the axillary, brachial, common iliac, internal iliac, and renal arteries, generating pulsatile masses or peripheral ischemic phenomena.

Synovial Joint Microanatomy and Sterile Vasculitic Synovitis

The musculoskeletal presentation of Kawasaki disease centers on diarthrodial joints, specifically large lower extremity weight-bearing articulations (knee, hip, ankle). The synovial membrane lines the non-cartilaginous internal surfaces of the fibrous capsule and consists of two functional zones:

• Synovial Intima (Intimal Cell Layer): A 1- to 3-cell-thick non-epithelial layer containing type A macrophage-like synoviocytes (specialized for phagocytosis and antigen processing) and type B fibroblast-like synoviocytes (responsible for synthesizing lubricin and hyaluronic acid).
• Synovial Subintima: Composed of vascularized, loose, areolar, or adipose connective tissue possessing an extensive capillary network with fenestrated endothelial walls. In Kawasaki disease, immune complex deposition and systemic cytokine amplification induce a primary microvascular endarteritis within these subintimal capillary beds.
• Cartilage-Sparing Mechanism: Unlike bacterial septic arthritis, in which pyogenic organisms trigger massive intra-articular neutrophil lysis, chondrolytic protease release (elastase, collagenase), and rapid irreversible destruction of hyaline articular cartilage within 24 to 48 hours, Kawasaki synovitis is a sterile, immunologically mediated serositis. The underlying articular chondrocytes and extracellular aggrecan-type II collagen framework remain structurally undamaged.

Cervical Lymphatic Anatomy and Differential Topography

Cervical lymphadenopathy in Kawasaki disease demonstrates a specific predilection for the deep anterior cervical triangle (internal jugular chain, level II and level III nodes). The nodes are typically unilateral, measuring 1.5 cm or greater in diameter, firm, and non-fluctuant. They reside along the anterior border of the sternocleidomastoid muscle, superficial to the carotid sheath containing the common carotid artery, internal jugular vein, and vagus nerve. Histologically, these nodes show intense lymphoid hyperplasia with follicular lysis, endothelial swelling, and microthrombosis, but completely lack the purulent liquefaction and abscess formation characteristic of bacterial adenitis (such as Staphylococcus aureus or group A Streptococcus) or deep neck space infections (retropharyngeal and parapharyngeal space phlegmons).

Peripheral Microvasculature and Acral Integument

The striking acral changes of Kawasaki disease reflect microvascular endarteritis of terminal dermal papillary capillaries and arteriovenous anastomoses in the palmar and plantar surfaces. In the acute phase, severe endothelial hyperpermeability produces dense dermal interstitial edema and intense erythema. Because the thick stratum corneum of the infant palm and sole is tethered by dense vertical fibrous septa to the palmar and plantar aponeuroses, this manifests clinically as painful, tense, indurated, non-pitting tumefaction. During the subacute phase (weeks 2 to 3), as microvascular inflammation subsides and the epidermal basement membrane recovers, rapid turnover leads to full-thickness sheet-like peeling (desquamation) initiating precisely at the junction of the nail bed and the distal digital pulp (periungual groove).

3. Pathogenesis

The pathogenesis of Kawasaki disease involves a genetically conditioned, dysregulated immune cascade triggered by an infectious stimulus, leading to self-amplifying systemic cytokine release and transmural medium-vessel destruction.

Genetic Susceptibility and Immunological Triggers

Epidemiological patterns, twin concordance rates, and genome-wide association studies (GWAS) confirm a potent host genetic predisposition. Key validated susceptibility loci include:

• ITPKC (Inositol 1,4,5-Trisphosphate 3-Kinase C): Functional single-nucleotide polymorphisms (SNPs) within the ITPKC gene reduce its expression, attenuating its normal inhibitory phosphorylation of IP3. This results in sustained intracellular calcium mobilization, leading to hyperactivation of the calcineurin-NFAT (nuclear factor of activated T cells) transcriptional axis, prolonged T-cell activation, and massive interleukin-2 (IL-2) secretion.
• CASP3 (Caspase-3): Polymorphisms within CASP3 impair activation-induced cell death in lymphocytes, permitting sustained survival of auto-reactive T-cell clones.
• FCGR2A (Fc Gamma Receptor IIa): An H131R polymorphism within the FCGR2A gene alters binding affinity for human IgG subclasses, modulating macrophage activation and clearance of immune complexes.
• Triggering Agent: Although a single universal pathogen has not been isolated, clinical features and epidemiological outbreaks suggest an infectious trigger (likely viral RNA sequences, coronavirus, or ubiquitous respiratory agents) that enters through the respiratory tract in a genetically susceptible child, activating a mucosal IgA immune response that disseminates systemically.

Triphasic Vasculopathic Evolution

Histopathological investigations of autopsy and explanted specimens define three continuous, overlapping pathological phases within the coronary artery wall:

• Phase 1: Acute Necrotizing Arteritis (Days 1 to 9): Synchronous with the initial febrile spike, an intense, destructive neutrophilic wave infiltrates the tunica intima and adventitia of coronary vessels. Neutrophils release proteolytic enzymes, including matrix metalloproteinases (MMP-2 and MMP-9) and neutrophil elastase, which rapidly cleave internal elastic lamina fibers and degrade media collagen. This induces structural wall necrosis within the first 7 to 9 days, creating focal weaknesses that can rapidly dilate into saccular aneurysms vulnerable to early rupture.
• Phase 2: Subacute / Chronic Vasculitis (Days 10 to 25 and beyond): Neutrophils are progressively replaced by a dense lymphohistiocytic infiltrate dominated by CD8+ cytotoxic T lymphocytes, CD68+ monocytes/macrophages, and oligoclonal IgA-producing plasma cells. Ongoing adventitial and medial inflammation promotes progressive cylindrical and fusiform vascular enlargement. Thrombosis readily occurs in areas of severe endothelial denudation and blood flow stasis.
• Phase 3: Luminal Myofibroblastic Proliferation and Remodeling (Months to Years): During convalescence, surviving adventitial fibroblasts and vascular smooth muscle cells undergo phenotypic transdifferentiation into migratory myofibroblasts under the driving influence of platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta). These myofibroblasts migrate into the disrupted intima, generating exuberant fibromuscular intimal hyperplasia. Over years, this proliferative scar tissue causes severe progressive coronary lumen stenosis, segmental occlusion, neo-vascularization, and extensive dystrophic calcification.

Musculoskeletal Pathophysiology and Synovial Fluid Dynamics

Joint involvement in Kawasaki disease occurs via two distinct temporal patterns:

• Acute Phase Arthritis (Days 1 to 10): Direct synovial microvascular vasculitis driven by circulating immune complexes and elevated circulating tumor necrosis factor-alpha (TNF-alpha), interleukin-1-beta (IL-1beta), and interleukin-6 (IL-6). This produces an acute, severe inflammatory synovial effusion predominantly targeting large lower extremity joints (knee, hip, ankle). Synovial fluid leukocyte counts typically range from 10,000 to 50,000 cells/microL with 60% to 80% neutrophils, occasionally reaching 80,000 cells/microL, closely mimicking an early septic process.
• Subacute / Convalescent Phase Arthritis (Weeks 2 to 6): Oligo- or polyarticular involvement often affecting smaller joints (hands, wrists, feet) associated with marked thrombocytosis and circulating immune complexes. This phase resembles reactive arthritis and resolves fully without articular erosion.

4. Natural History

Without targeted medical intervention, Kawasaki disease follows a stereotypic natural history driven by progressive vascular and systemic inflammation.

Global Epidemiology and Demographic Risk Profile

Kawasaki disease is recognized worldwide across all racial and ethnic groups, but demonstrates marked geographic and genetic variation:

• Incidence by Geographic Region: The highest annual incidence occurs in Northeast Asian populations. In Japan, nationwide surveys document an incidence exceeding 300 to 350 per 100,000 children younger than 5 years old. South Korea and Taiwan report annual rates between 150 and 200 per 100,000. In North America and Western Europe, the incidence ranges from 15 to 25 per 100,000 children under 5 years of age.
• Age Distribution: Fully 80% to 85% of cases occur in children aged between 6 months and 5 years, with the single highest peak between 18 and 24 months. Disease onset in infants younger than 6 months is less common, but carries the highest risk of incomplete presentation, diagnostic delay, and giant aneurysm development.
• Sex Predilection and Seasonality: A consistent male-to-female predominance exists worldwide (approximately 1.5:1). In temperate climates, cases cluster seasonally during late winter and early spring, with periodic epidemiological epidemics.

The Four Classical Clinical Phases

The untreated disease progresses through four distinct stages:

• 1. Acute Febrile Phase (Days 1 to 11): Characterized by high, remittent, spiking fevers (frequently exceeding 39.5°C to 40.0°C) unresponsive to standard antipyretics and broad-spectrum antibiotics. Classic mucocutaneous signs emerge sequentially. Marked systemic irritability, aseptic meningitis, acute myocarditis, and early large-joint arthritis predominate during this phase.
• 2. Subacute Phase (Days 11 to 25): Fever typically remits, but systemic vasculopathy peaks. Hallmark features include marked reactive thrombocytosis (platelet counts often exceeding 500,000 to 1,200,000/microL) and characteristic periungual sheet desquamation of fingers and toes. This phase carries the highest risk of coronary artery aneurysm expansion, acute coronary thrombosis, and sudden cardiac death.
• 3. Convalescent Phase (Weeks 4 to 8): All clinical signs of active inflammation subside. Acute-phase reactants (ESR, CRP) gradually return to normal baseline levels. Transverse Beau’s lines may appear across the fingernails, marking temporary nail matrix arrest during the acute febrile peak.
• 4. Chronic Phase (Months to Decades): Relevant exclusively in children who developed coronary artery aneurysms. Aneurysms may remain stable, remodel, or develop progressive fibromuscular intimal stenosis, calcification, and thrombosis, resulting in late exercise-induced myocardial ischemia, silent infarction, and accelerated adult atherosclerotic cardiovascular disease.

5. Clinical Presentation

Early identification of Kawasaki disease requires a high index of suspicion, combining a systematic clinical history with provocative physical examination maneuvers.

5.1 History

Clinicians must interrogate specific diagnostic and musculoskeletal history features:

• Fever Profile: Documentation of an unremitting, high-spiking fever lasting at least 5 days. Parents report transient, incomplete defervescence with acetaminophen or ibuprofen, with immediate rebound back to 39°C or 40°C.
• Failure of Empirical Antibiotics: A history of recent outpatient visits where the child was prescribed empirical oral antibiotics (such as amoxicillin, amoxicillin-clavulanate, or cephalexin) for suspected streptococcal pharyngitis, acute otitis media, or cervical lymphadenitis without clinical improvement.
• Musculoskeletal and Gait Disturbance: Sudden onset of limp, inability or refusal to bear weight, refusal to walk, or crawling to avoid standing. Parents often note the child guarding a hip or knee, crying when placed in a standing position, or exhibiting morning stiffness that improves slightly with warmth.
• Extreme Irritability: A degree of distress, crying, and inconsolability completely out of proportion to physical findings, reflecting underlying sterile aseptic meningitis.
• Associated Systemic Symptoms: Gastrointestinal complaints occur in over 30% of patients, including colicky abdominal pain, vomiting, diarrhea, and rarely hydrops of the gallbladder with jaundice. Cough and rhinorrhea may be present, often confusing initial presentation with an upper respiratory viral illness.

5.2 Physical Exam

The physical examination must systematically assess diagnostic mucocutaneous signs, joint pathology, and cardiovascular stability:

Provocative orthopaedic and clinical examination maneuvers must be conducted systematically:

• Hip Log-Roll Maneuver: With the child supine, the examiner gently rotates the lower extremity internally and externally with the knee in full extension. Positive finding: In bacterial septic arthritis, severe capsular distention triggers agonizing pain and unyielding reflex muscle spasm throughout the arc of motion. In Kawasaki synovitis, while end-range internal rotation is uncomfortable, gentle mid-arc rotation is typically well tolerated without rigid involuntary guarding.
• Knee Ballotable Patella and Bulge Test: The suprapatellar pouch is compressed downward with one hand while the patella is tapped against the femoral trochlea with the contralateral index finger. Positive finding: A palpable tap and floating sensation indicate a tense joint effusion, commonly seen in acute Kawasaki synovitis.
• Active Refusal to Walk vs. Passive Arc Preservation: The child is observed attempting weight-bearing, demonstrating an antalgic limp or complete refusal to stand. However, when placed in a parent’s lap and examined with gentle distraction, passive flexion-extension of the knee and hip shows preserved arcs of motion, contrasting with the absolute splinting of acute bacterial osteoarticular infection.
• Bulbar Perilimbal Sparing Test: Retraction of the palpebrae reveals profound dilatation of conjunctival vessels that abruptly terminates 1 to 2 mm from the corneal limbus, leaving an avascular clear halo. Absence of photophobia and pupillary constriction distinguishes it from acute anterior uveitis.

6. Imaging and Diagnostic Studies

Establishing the diagnosis of Kawasaki disease and distinguishing its joint manifestations from acute septic arthritis relies upon an integrated imaging and laboratory hierarchy.

Cardiovascular Imaging: Transthoracic Echocardiography (Gold Standard)

Transthoracic echocardiography (TTE) is the definitive, mandatory imaging modality for assessing cardiovascular involvement. An initial baseline echocardiogram should be performed as soon as Kawasaki disease is suspected, repeated at 1 to 2 weeks, and again at 4 to 6 weeks after treatment completion in uncomplicated cases:

• Anatomical Sizing via Body Surface Area (BSA) Z-Scores: Internal vessel diameters must be normalized to body surface area using validated Z-scores rather than absolute millimeter dimensions, because infant vessels vary substantially across growth percentiles. The proximal left main coronary artery (LMCA), proximal left anterior descending (LAD), and proximal right coronary artery (RCA) are measured from inner-edge to inner-edge in standard parasternal short-axis and long-axis views.
• Qualitative Vascular Features: Early signs include perivascular brightness (echogenicity) along coronary arterial walls, lack of normal tapering, and focal luminal irregularity.
• Myocardial and Valvular Assessment: Evaluation of left ventricular systolic function (ejection fraction, fractional shortening), detection of small-to-moderate pericardial effusions, and assessment of mitral regurgitation resulting from acute papillary muscle dysfunction or myocarditis.

Musculoskeletal Imaging: Plain Radiography and Ultrasound

When a child presents with an acute joint effusion, imaging must differentiate sterile Kawasaki synovitis from bacterial septic arthritis and osteomyelitis:

• Plain Radiographs: Anteroposterior (AP) and frog-leg lateral radiographs of the pelvis/hips, and AP and lateral views of the knees or ankles. Findings in Kawasaki disease are strictly non-osseous, revealing soft tissue swelling, capsular distention, and displacement of normal periarticular fat lines (such as the gluteus medius fat stripe or suprapatellar fat pad). Radiographs are completely devoid of cortical destruction, periosteal new bone formation, or subchondral bone erosion.
• High-Resolution Musculoskeletal Ultrasound (MSK-US): Rapid, non-invasive first-line assessment of the hip or knee. For the hip, imaging along the anterior femoral neck measures the anterior capsule-to-bone distance: an effusion is confirmed if the distance exceeds 5 mm or if an asymmetry greater than 2 mm exists compared to the asymptomatic contralateral hip. In Kawasaki disease, fluid is typically anechoic or hypoechoic without thick septations, while power Doppler confirms mild-to-moderate synovial vascularity.

Advanced Imaging: Magnetic Resonance Imaging (MRI) and CT Angiography

When clinical signs overlap heavily with acute hematogenous osteomyelitis (AHO) or deep space infection, advanced imaging resolves diagnostic ambiguity:

• Musculoskeletal MRI: Dedicated multiplanar MRI of the affected limb with T1, T2 fat-suppressed (or STIR), and post-gadolinium sequences. In Kawasaki synovitis, MRI confirms prominent synovial enhancement and joint effusion, but critically rules out acute osteomyelitis by demonstrating normal bone marrow signal intensity (no T1 hypointensity or STIR hyperintensity within metaphysis or epiphysis) and confirming the absence of subperiosteal abscesses, intraosseous phlegmons, or pyomyositis.
• Coronary CT Angiography (CCTA) and Cardiac MRI: Utilized in older children, patients with poor acoustic windows, or complex/giant aneurysms to assess branching vessels, distal coronary branches, luminal thrombosis, and myocardial viability/fibrosis via late gadolinium enhancement (LGE).

Laboratory Hierarchy and Synovial Fluid Differentiation

Laboratory testing provides essential support for the clinical diagnosis and risk stratification:

• Hematology and Reactive Thrombocytosis: Marked leukocytosis with prominent neutrophilic predominance and left shift (immature band forms exceeding 5%); normocytic, normochromic anemia reflecting active cytokine-mediated suppression of erythropoiesis; and progressive thrombocytosis. In the first 7 days, platelet counts are often normal or slightly low; during the second week, counts rise dramatically (frequently exceeding 500,000 to 1,200,000/microL), serving as a powerful diagnostic clue.
• Acute Phase Reactants: C-reactive protein (CRP) is elevated (at or above 30 mg/L) and erythrocyte sedimentation rate (ESR) is accelerated (at or above 40 mm/hr, often exceeding 80 to 100 mm/hr). CRP is the superior biomarker for monitoring therapeutic response, because exogenous IVIG artificially inflates the ESR through red blood cell rouleaux formation.
• Biochemical and Urinalysis Markers: Serum albumin drops below 3.0 g/dL due to systemic vascular leakage and decreased hepatic synthesis; serum transaminases (ALT/AST) and gamma-glutamyl transferase (GGT) are frequently elevated; serum sodium drops below 135 mmol/L (SIADH-like state correlating with IVIG resistance); clean-catch unspun urinalysis demonstrates sterile pyuria (at least 10 WBC per high-power field) arising from non-infectious urethritis.
• Synovial Fluid Analysis (Arthrocentesis): If diagnostic aspiration is performed for a suspected septic joint, Kawasaki synovial fluid is turbid to straw-colored; leukocyte counts typically range from 10,000 to 50,000 cells/microL with 60% to 80% neutrophils; synovial glucose matches serum levels (above 50 mg/dL); Gram stain is negative; and bacterial cultures and universal 16S bacterial PCR remain completely sterile. In contrast, true bacterial septic arthritis yields thick purulent fluid with leukocyte counts typically exceeding 50,000 to 100,000 cells/microL, marked neutrophil predominance (above 85% to 90%), profound hypoglycorrhachia (fluid glucose below 40 mg/dL or below 50% of blood glucose), and positive Gram stains in 40% to 60% of cases.

7. Classification

Standardized classification systems guide diagnostic confirmation, cardiovascular risk stratification, and identification of refractory disease.

American Heart Association Diagnostic Classification

Coronary Artery Lesion Classification by AHA Z-Scores

Kobayashi Score for Prediction of IVIG Resistance

8. Treatment

Management of Kawasaki disease emphasizes rapid suppression of systemic vascular inflammation, prevention of thrombosis, and nonoperative joint preservation.

Medical / Nonoperative

Primary medical therapy must be initiated as soon as the clinical diagnosis is suspected:

• Intravenous Immunoglobulin (IVIG): The cornerstone of primary therapy. Administered as a single intravenous infusion of 2 g/kg over 10 to 12 hours. Initiation within the first 10 days of fever onset is critical; however, IVIG must still be administered to children presenting after day 10 if unexplained fever persists, or if coronary abnormalities are detected alongside elevated systemic inflammatory markers (CRP, ESR). Mechanistically, IVIG delivers immediate anti-inflammatory action via endothelial Fc-receptor saturation, modulation of pro-inflammatory cytokines, neutralization of circulating toxins, and induction of regulatory T cells.
• Aspirin (Acetylsalicylic Acid, ASA): Co-administered with initial IVIG. In the acute phase, anti-inflammatory dosing is prescribed: either moderate-dose (30 to 50 mg/kg/day divided every 6 hours) or high-dose (80 to 100 mg/kg/day divided every 6 hours). This anti-inflammatory dose is maintained until the patient remains afebrile for 48 to 72 hours. The regimen is then converted to low-dose antiplatelet aspirin (3 to 5 mg/kg/day administered orally once daily) and maintained for 6 to 8 weeks in patients with normal coronaries, or continued indefinitely if coronary aneurysms develop.
• Primary Adjunctive Corticosteroids in High-Risk Patients: In children identified as high risk for IVIG failure (such as Kobayashi score of 5 or greater in Japanese cohorts or severe clinical presentation), primary addition of intravenous prednisolone (2 mg/kg/day divided every 8 hours) tapered over 2 to 3 weeks alongside standard IVIG and aspirin significantly reduces coronary aneurysm rates.
• Management of Refractory / IVIG-Resistant Disease: Approximately 10% to 20% of patients experience persistent or recrudescent fever 36 hours after completion of initial IVIG. Validated rescue options include a second IVIG infusion (2 g/kg), intravenous pulse methylprednisolone (30 mg/kg/day for 3 days), infliximab (5 mg/kg single infusion), or cyclosporine A (4 to 5 mg/kg/day) / anakinra (2 to 6 mg/kg/day subcutaneously) for refractory vasculitis.
• Antithrombotic Regimens for Aneurysmal Disease: Patients with medium aneurysms (Z 5 to 10) require dual antiplatelet therapy (aspirin 3 to 5 mg/kg/day plus clopidogrel 1 mg/kg/day). Patients with giant aneurysms (Z at or above 10 or diameter at or above 8 mm) mandate systemic anticoagulation (low-molecular-weight heparin with target anti-Xa 0.5 to 1.0 U/mL, or warfarin with target INR 2.0 to 3.0) combined with low-dose antiplatelet aspirin.

Operative

Surgical principles in Kawasaki disease emphasize nonoperative joint protection and targeted cardiovascular revascularization:

• Orthopaedic Management: Avoidance of Unwarranted Surgical Arthrotomy: The primary orthopaedic mandate is joint preservation through the avoidance of unnecessary open or arthroscopic arthrotomy. If diagnostic needle arthrocentesis was performed to exclude septic arthritis, no formal surgical drainage, catheter placement, or debridement is indicated once fluid is confirmed sterile and non-purulent. Kawasaki synovitis responds rapidly to IVIG and anti-inflammatory therapy, achieving complete effusion resorption within days without chondral damage.
• Coronary Artery Bypass Grafting (CABG): Indicated for children or adolescents who develop severe localized or multivessel coronary artery stenoses, ischemic cardiomyopathy, or thrombosed giant aneurysms refractory to interventional catheterization. The internal thoracic artery (internal mammary artery, ITA/LIMA) is the graft conduit of choice, because it exhibits somatic growth potential alongside the developing pediatric thoracic skeleton and maintains superior long-term patency compared to saphenous vein grafts.
• Percutaneous Coronary Intervention (PCI): In older children and adolescents with discrete, focal, non-calcified coronary stenoses, balloon angioplasty or coronary stent implantation may be performed in specialized centers. Rotational atherectomy is reserved for heavily calcified late stenotic lesions.
• Orthotopic Cardiac Transplantation: The definitive end-stage option for children who develop severe ischemic cardiomyopathy, extensive myocardial necrosis, or intractable ventricular arrhythmias refractory to revascularization.

Indications & Contraindications

Explicit clinical thresholds dictate operative and nonoperative decisions:

• Indications for Primary Medical Therapy: Confirmed classic Kawasaki disease (fever for 5 or more days plus 4 criteria) or confirmed incomplete Kawasaki disease (fever with 2 or 3 criteria and elevated CRP/ESR alongside supporting lab or echo criteria). Treatment is initiated immediately within the 10-day window, or beyond day 10 in the presence of ongoing fever, elevated inflammatory markers, or dynamic coronary changes.
• Indications for Diagnostic Arthrocentesis: Presence of an acute, tense monoarticular joint effusion with fever, high inflammatory markers, and severe refusal to walk, where true bacterial septic arthritis cannot be safely ruled out on clinical grounds prior to confirming classic mucocutaneous signs of Kawasaki disease.
• Contraindications to Open Surgical Arthrotomy: Open or arthroscopic joint debridement is strictly contraindicated in patients with established Kawasaki disease who demonstrate non-purulent, sterile synovial aspirates, negative Gram stains, and preserved synovial glucose.
• Indications for Pediatric CABG: Severe left main coronary stenosis exceeding 50%; multi-vessel proximal coronary stenosis exceeding 75%; reversible ischemia documented on exercise stress testing or nuclear perfusion imaging; or symptomatic recurrent angina following giant aneurysm thrombosis.

9. Outcome

Long-term clinical outcomes in Kawasaki disease depend upon the severity of coronary arterial injury and the timeliness of primary anti-inflammatory therapy.

Cardiovascular Remodeling and Long-Term Survivorship

The cardiovascular prognosis is directly dictated by coronary Z-scores documented during the subacute phase:

• Small-to-Medium Aneurysm Regression (Z-scores 2.5 to 5.0): Approximately 50% to 70% of small- and medium-sized coronary aneurysms undergo angiographic remodeling and return to normal luminal dimensions within 1 to 2 years after disease onset. However, intravascular ultrasound (IVUS) and histopathological studies demonstrate that even when the lumen appears angiographically normal, the vessel wall remains abnormal, characterized by myointimal thickening, focal calcification, and impaired endothelium-dependent vasodilation.
• Giant Aneurysm Fate (Z-scores at or above 10 or diameter at or above 8 mm): Giant aneurysms rarely remodel back to normal caliber. Longitudinal registry analyses indicate that up to 50% of giant aneurysms develop progressive thrombosis, severe segmental stenosis, or myocardial infarction within 10 to 20 years. Lifelong therapeutic anticoagulation and regular non-invasive cardiac testing are mandatory.
• Overall Case-Fatality Rate: With early IVIG and aspirin therapy, overall pediatric mortality is less than 0.05% to 0.1% in developed countries. Fatalities are almost exclusively attributable to acute coronary thrombosis during the subacute phase (weeks 2 to 4) or sudden late ischemic arrhythmias in young adulthood.

Musculoskeletal Resolution and Functional PROMs

In contrast to the potential for chronic vascular morbidity, the musculoskeletal prognosis of Kawasaki disease is excellent:

• Complete Joint Recovery Without Cartilage Destruction: Gong et al. and prospective cohort studies confirm that acute arthritis and sterile synovial effusions resolve completely in 100% of patients following successful administration of IVIG and anti-inflammatory therapy. Joint effusion and tenderness subside within a median of 3 to 5 days after fever resolution. There is zero risk of secondary chondrolysis, joint space narrowing, permanent contracture, or chronic juvenile idiopathic arthritis.
• Functional Outcomes and Patient-Reported Outcome Measures (PROMs): Pediatric quality-of-life assessments (such as the Pediatric Quality of Life Inventory, PedsQL) demonstrate complete recovery of age-appropriate physical mobility, crawling, and gait kinematics within 4 to 8 weeks. Physical activity is uninhibited in children with normal coronaries; children with giant aneurysms are restricted from collision and competitive contact sports to prevent coronary rupture and traumatic bleeding complications associated with systemic anticoagulation.

10. Complications

Complications in Kawasaki disease span cardiovascular, musculoskeletal, and systemic organ systems across acute, subacute, and chronic timeframes:

11. Pearls and Pitfalls

Distinguishing Kawasaki disease from surgical orthopaedic emergencies requires vigilance and adherence to proven clinical pearls:

• The “Look at the Eyes, Mouth, and Groin” Rule in Pediatric Limp: When evaluating a child presenting to the emergency department with fever, limp, and elevated inflammatory markers concerning for a septic hip, perform a complete head-to-toe skin examination. Carefully look for perilimbal-sparing bulbar conjunctival injection, dry cracked lips, a strawberry tongue, and bright red erythema in the diaper or perineal region. Missing these signs leads directly to misdiagnosing the condition as an isolated orthopaedic infection.
• Preserved Passive Arc vs. Absolute Septic Guarding: In true bacterial septic arthritis, capsular distention triggers agonizing pain with even 5 degrees of gentle passive rotation, accompanied by severe involuntary reflex muscle spasm. In Kawasaki synovitis, although active weight-bearing is rejected, gentle passive joint range of motion can be achieved with modest discomfort, especially when the child is calm and distracted.
• The Second-Week Thrombocytosis Clue: Normal platelet counts during the first 3 to 5 days of fever do not rule out Kawasaki disease. In fact, a normal or low-normal platelet count is typical during the acute phase; massive thrombocytosis (500,000 to over 1,000,000/microL) emerges during the second week (days 10 to 14). Rechecking complete blood counts in a child with unresolving fever can confirm the diagnosis.
• The Post-IVIG ESR Pitfall: Never use the erythrocyte sedimentation rate (ESR) to gauge treatment response or monitor for disease recurrence following IVIG administration. Exogenous pooled human immunoglobulin drastically accelerates erythrocyte rouleaux formation, causing a massive artificial rise in the ESR that can persist for weeks. Always monitor serum C-reactive protein (CRP) and clinical fever curves to assess therapeutic success.
• Synovial Fluid Glucose Differentiation: If an acute monoarticular effusion is aspirated to exclude septic arthritis, prioritize an immediate STAT Gram stain and synovial glucose level. In Kawasaki disease, synovial glucose is normal (above 50 mg/dL or identical to serum glucose), Gram stain is negative, and cell counts are typically 10,000 to 50,000 cells/microL. Immediate pediatric cardiology consultation and echocardiography should take precedence over open arthrotomy.
• High-Dose Aspirin and Live Virus Exposure: For patients maintained on low-dose aspirin for coronary aneurysms, ensure family counseling regarding Reye’s syndrome. In the event of confirmed varicella or active influenza exposure, immediately discontinue aspirin and switch to clopidogrel (1 mg/kg/day) until the viral illness resolves.
• The Infant Under 6 Months Dilemma: Incomplete presentations are most common in infants under 6 months old, who often present solely with prolonged fever and irritability without classic rash or conjunctivitis. These patients have the highest risk of developing giant coronary aneurysms. Any infant under 6 months with unexplained fever lasting 7 days or more requires an echocardiogram and complete inflammatory biomarker screening.

12. Controversy

Several major controversies persist regarding optimal medical dosing, primary risk stratification, second-line immunomodulatory therapy, and perioperative management in Kawasaki disease:

• Aspirin Dosing in the Acute Phase: High-Dose versus Moderate-Dose Regimens: Marked international divergence exists regarding the initial dose of aspirin administered alongside IVIG. North American protocols traditionally utilized high anti-inflammatory doses (80 to 100 mg/kg/day divided every 6 hours), whereas Japanese, European, and Australasian centers routinely employ moderate anti-inflammatory doses (30 to 50 mg/kg/day) or even low antiplatelet doses (3 to 5 mg/kg/day). Contemporary multicenter retrospective studies and systematic meta-analyses demonstrate no significant difference in the incidence of coronary artery aneurysms, duration of fever, or rates of IVIG resistance between high- and moderate-dose cohorts. Because high-dose aspirin carries higher risks of transient chemical hepatotoxicity, gastritis, and ototoxicity without clear cardiovascular superiority, international consensus is increasingly shifting toward moderate dosing during the acute febrile window.
• Universal versus Risk-Stratified Primary Corticosteroid Therapy: The landmark RAISE trial (Kobayashi et al., 2012) demonstrated that adding primary intravenous prednisolone to standard IVIG and aspirin in high-risk Japanese children (Kobayashi score of 5 or greater) dramatically reduced coronary artery abnormalities from 23% down to 3%. However, when the Kobayashi scoring system is applied to ethnically diverse North American and Western European pediatric cohorts, its sensitivity for identifying IVIG resistance drops below 40% to 50%, limiting its predictive utility in Western populations. Whether primary adjunctive systemic corticosteroids should be administered universally to all patients with Kawasaki disease, restricted to Asian populations, or guided by novel biomarker panels remains actively debated.
• Optimal Second-Line Immunomodulatory Agent in IVIG Resistance: Approximately 10% to 20% of patients fail to defervesce following initial IVIG, placing them at severe risk for aneurysm formation. The choice of second-line rescue therapy remains controversial, with treatment strategies varying between a second dose of IVIG (2 g/kg), high-dose intravenous pulse methylprednisolone (30 mg/kg/day for 3 days), infliximab (5 mg/kg), and anakinra (IL-1 receptor antagonist). Randomized trials have shown that infliximab achieves faster defervescence and shorter hospital stays compared to a second IVIG infusion; however, definitive evidence proving superiority in long-term coronary Z-score regression is still under active investigation.
• Anesthetic and Perioperative Collapse in Misdiagnosed Kawasaki Vasculitis: When a child with unrecognized Kawasaki disease is mistakenly taken to the operating room for emergency hip or knee arthrotomy under general anesthesia, acute myocarditis, impaired left ventricular ejection fraction, and active coronary vasculitis create severe hemodynamic vulnerability. Induction agents and positive-pressure ventilation can trigger profound vasodilation, refractory cardiogenic shock, malignant ventricular arrhythmias, or perioperative cardiac arrest. This underscores the imperative for thorough preoperative medical evaluation and pediatric cardiology clearance before undertaking non-emergent surgical interventions.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• McCrindle BW, Rowley AH, Newburger JW et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017. doi:10.1161/CIR.0000000000000484 [Level IV: Clinical Practice Guideline / Consensus Statement]
• Newburger JW, Takahashi M, Beiser AS et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991. doi:10.1056/NEJM199106063242305 [Level I: Randomized Controlled Trial]
• Kobayashi T, Saji T, Otani T et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012. doi:10.1016/S0140-6736(11)61930-2 [Level I: Randomized Controlled Trial]
• Gong GW, McCrindle BW, Ching JC et al. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr. 2006. doi:10.1016/j.jpeds.2006.01.039 [Level IV: Clinical Case Series / Cohort Study]
• Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986. doi:10.1056/NEJM198608073150601 [Level I: Randomized Controlled Trial]

15. Master Class Pro-Tip

The Orthopaedic Trap: Kawasaki Disease Masquerading as Pediatric Septic Arthritis: An orthopaedic on-call surgeon’s nightmare is missing a septic hip; yet rushing a toddler with fever and a painful, non-weight-bearing lower extremity into the operating room for an emergency arthrotomy without a systemic survey can be catastrophic. Kawasaki disease frequently manifests in the acute phase as sterile, inflammatory oligoarthritis of the hip or knee, accompanied by high unremitting fever, marked leukocytosis, and extreme ESR and CRP elevations that easily fulfill Kocher criteria for septic arthritis. Before draping for an operative incision, strip the child completely: inspect the bulbar conjunctiva for non-exudative injection with classic perilimbal sparing, examine the vermilion border and tongue for strawberry changes, look for perineal desquamation or palm erythema, and palpate the cervical chain. If arthrocentesis reveals turbid fluid, immediately obtain a STAT Gram stain and synovial glucose: in Kawasaki disease, the fluid is sterile and glucose is preserved (above 50 mg/dL or concordant with blood glucose). If clinical suspicion for Kawasaki disease exists, abort open surgical arthrotomy, hold broad-spectrum vancomycin, and obtain an emergency STAT pediatric echocardiogram. Commencing 2 g/kg IVIG and aspirin halts coronary vasculitis within hours, prevents life-threatening giant aneurysm formation, and produces dramatic, rapid resolution of joint pain and effusions without cartilage damage or surgical morbidity.

Master Class Surgical Pearl: Kawasaki Disease vs. Pediatric Septic Arthritis